Inside Co-Diagnostics’ Saudi Arabia expansion: the CoMira JV bringing PCR manufacturing to the MENA region

Co-Diagnostics Inc. (NASDAQ: CODX) has signed a definitive joint-venture agreement with Arabian Eagle Manufacturing to establish CoMira Diagnostics, a new company based in the Kingdom of Saudi Arabia that will localize and commercialize the Co-Dx PCR platform across the Middle East and North Africa. The agreement represents a major regional expansion for the Utah-based molecular diagnostics developer, whose technology portfolio includes PCR-based infectious disease testing platforms and point-of-care diagnostic systems.

Under the terms of the deal, CoMira Diagnostics will receive an exclusive license from Co-Diagnostics to research, develop, assemble, and distribute the Co-Dx platform and associated assays throughout Saudi Arabia and 18 other MENA markets. Arabian Eagle will manage the local manufacturing facility setup, regulatory submissions to the Saudi Food and Drug Authority (SFDA), and logistics and compliance under the country’s Vision 2030 framework.

The partnership signals a deliberate shift by Co-Diagnostics toward local production and regional market access, positioning the company at the center of a high-growth diagnostics landscape where government policy increasingly favors domestic manufacturing and healthcare self-sufficiency.

How the CoMira Diagnostics joint venture positions Co-Diagnostics in a regional leadership role across Saudi Arabia and the MENA markets

The new venture, CoMira Diagnostics, will serve as the exclusive entity for deploying Co-Dx intellectual property in the region, covering 19 territories including Saudi Arabia, the United Arab Emirates, Qatar, Oman, Egypt, Morocco, and Turkey. This model allows Co-Diagnostics to retain control over its proprietary PCR technology while leveraging Arabian Eagle’s local industrial experience and regulatory alignment.

According to the company, the joint venture is designed to support the key pillars of Saudi Vision 2030, which emphasizes localization of manufacturing, technology transfer, and healthcare innovation. The facility will manufacture and assemble Co-Dx devices and reagents locally, providing the Kingdom and neighboring countries with rapid access to high-quality PCR diagnostics while strengthening regional supply-chain resilience.

Co-Diagnostics said the Co-Dx PCR platform will form the technological backbone of this venture. The system includes the upcoming Co-Dx PCR Home™ and Co-Dx PCR Pro™ instruments, supported by a companion mobile app, enabling near-patient molecular testing with centralized cloud-based data integration. These devices are intended to deliver laboratory-grade accuracy in decentralized healthcare settings, although they are not yet cleared for sale in any market.

The launch of CoMira Diagnostics comes at a pivotal time when the MENA region’s diagnostic testing demand continues to surge post-pandemic, driven by public-health initiatives, population screening programs, and the growth of private healthcare providers. For Co-Diagnostics, a company seeking to transition from research and development to global commercialization, this venture could serve as a key catalyst for expanding recurring revenue streams from reagent sales and service contracts.

Why the Saudi Vision 2030 framework and regulatory pathway could accelerate diagnostics localization for CoMira

Industry observers note that Saudi Arabia’s Vision 2030 program is now driving an aggressive localization push across healthcare technology sectors. By manufacturing in-country and achieving SFDA regulatory approval, CoMira Diagnostics could gain preferential access to government contracts and regional export advantages under GCC trade frameworks.

Arabian Eagle Manufacturing’s role in establishing and operating the Saudi facility is central to the plan. The company will lead all activities related to regulatory registration, quality assurance, logistics, and after-sales support, ensuring compliance with both SFDA and international ISO 13485 standards. Once SFDA clearance is secured, CoMira plans to extend distribution to the broader MENA region through local partnerships, adapting to each country’s regulatory framework.

Analysts describe this as a de-risking strategy for Co-Diagnostics. Instead of navigating 19 separate regulatory environments directly, the company will rely on CoMira’s regional presence and Arabian Eagle’s operational expertise to shorten time-to-market and lower capital exposure. This also positions Co-Diagnostics to benefit from incentives for technology transfer and job creation under Vision 2030’s National Industrial Strategy.

How the Co-Dx PCR platform pipeline and clinical timeline could determine the success of the regional expansion

Co-Diagnostics reported that several assays for the Co-Dx PCR platform are entering clinical evaluation before the end of 2025. These include a multiplex test for tuberculosis, an eight-type HPV panel, and an upper-respiratory assay covering influenza A/B, COVID-19, and RSV. These product lines are expected to anchor CoMira’s initial manufacturing roadmap, pending regulatory clearance.

The company’s next-generation Co-Dx PCR platform aims to bring molecular testing closer to the point of care, minimizing dependence on centralized laboratory infrastructure. The system’s modularity and small-footprint design make it suitable for hospital networks, rural clinics, and mobile healthcare programs—a priority segment across the MENA region, where diagnostic infrastructure can vary widely.

Co-Diagnostics has indicated that data from the ongoing validation studies will be used to support regulatory filings not only in the United States but also in Saudi Arabia and other early-adoption markets under the CoMira partnership. This synchronized regulatory timeline may allow simultaneous product launches across several jurisdictions once SFDA approval is granted.

If these evaluations are completed on schedule, commercial deployment could begin in 2026, aligning with the broader regional rollout plan. The company said the Co-Dx platform’s design allows rapid reconfiguration for emerging pathogens, offering pandemic readiness that aligns with regional biosecurity priorities.

What investor sentiment reveals about market reaction to Co-Diagnostics’ Saudi joint venture announcement

Market reaction to the announcement has been highly positive. Following the news, Co-Diagnostics’ stock (NASDAQ: CODX) surged nearly 100 percent in intraday trading, briefly touching its highest levels in months before moderating. The surge reflects investor enthusiasm over the company’s first major international manufacturing partnership and its implications for long-term revenue visibility.

At the latest trading session, Co-Diagnostics shares were priced around US $0.83, reflecting a one-day gain of over 40 percent at one point, with trading volume exceeding 500 million shares—far above the daily average. Analysts attribute the bullish sentiment to the perception that the Saudi JV marks a transition from a technology-development narrative to a commercial execution phase for Co-Diagnostics.

Market data shows that Co-Diagnostics had a trailing twelve-month revenue base of roughly US $3.9 million and has been operating at a net loss, highlighting the transformative potential of a localized manufacturing and distribution network. While details of the financial structure of the joint venture were not disclosed, the exclusive territorial license suggests a recurring revenue component from royalties or technology fees.

Institutional sentiment has also been improving, with several retail and small-cap funds reportedly increasing exposure after the announcement. However, analysts continue to emphasize the execution risks—including regulatory timelines, capital expenditure for the Saudi facility, and the challenge of scaling production to meet regional demand.

How localization of diagnostics manufacturing aligns with global supply chain trends and MENA healthcare priorities

The CoMira Diagnostics venture reflects a broader global trend in decentralized manufacturing and regional supply-chain resilience for critical healthcare technologies. During the COVID-19 pandemic, MENA countries faced testing supply shortages due to reliance on imported diagnostics. By establishing a Saudi-based manufacturing hub, Co-Diagnostics and Arabian Eagle are addressing that vulnerability while aligning with the country’s ambition to become a regional hub for life-sciences innovation.

Saudi Arabia’s healthcare transformation plan aims to grow the domestic medical devices market to more than US $15 billion by 2030, with localization of diagnostics manufacturing as a top priority. Co-Diagnostics’ strategy leverages this policy environment, enabling local workforce development, technology transfer, and value-added industrial growth.

From a geopolitical perspective, the timing also coincides with renewed investment flows into healthcare manufacturing across the Gulf Cooperation Council (GCC). CoMira’s territory—spanning 19 MENA countries—represents a combined population of over 500 million people, offering Co-Diagnostics a vast addressable market for its PCR and multiplex assay technologies.

What milestones will determine the commercial and financial impact of CoMira Diagnostics for Co-Diagnostics shareholders

The immediate next steps include the establishment of CoMira’s manufacturing site, submission for SFDA regulatory clearance, and initiation of clinical evaluations for the platform’s first three assays. The company also expects to finalize its regional distribution framework once SFDA approval is secured, potentially positioning CoMira as a regional supplier to hospitals, reference labs, and public-health agencies.

Investors will be closely watching for updates on the joint venture’s financial structure, including equity ownership percentages, capital contributions, and revenue-sharing terms. These details will be key in assessing whether Co-Diagnostics captures a meaningful share of the venture’s profits or primarily benefits through licensing income.

Should the Saudi manufacturing facility become operational within the projected 12- to 18-month window, analysts estimate that regional production of Co-Dx tests could generate incremental annual revenues of US $15–20 million for Co-Diagnostics over the medium term. That projection remains contingent on product approvals and regional adoption rates, but it underscores the potential scale of the opportunity.

The strategic takeaway for Co-Diagnostics, Arabian Eagle, and investors watching the MENA diagnostics market

For Co-Diagnostics, the CoMira partnership represents more than a geographic expansion—it signals a strategic evolution from a niche molecular diagnostics developer into a global technology licensor and regional manufacturing enabler. By anchoring itself in Saudi Arabia’s Vision 2030 industrial framework, the company is positioning its PCR technology within one of the most ambitious healthcare-localization programs in the world.

Arabian Eagle Manufacturing, for its part, gains access to proprietary U.S.-developed molecular diagnostics technology and a pipeline of assays designed for both point-of-care and laboratory use. The collaboration aligns commercial interests with national policy goals while creating a potential export base for neighboring markets.

For investors, the opportunity carries both upside potential and high execution risk. Success will depend on regulatory progress, capital deployment discipline, and the company’s ability to convert exclusive territorial rights into sustainable market penetration. If Co-Diagnostics executes effectively, the Saudi partnership could mark the beginning of a new growth phase driven by recurring licensing and manufacturing revenue rather than sporadic pandemic-era test sales.